Bioqual (OTCMKTS:BIOQ – Get Free Report) issued its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, Zacks reports. Bioqual had a negative net margin of 9.75% and a negative return on equity of 11.20%.
Bioqual Stock Performance
Shares of Bioqual stock remained flat at $30.64 during mid-day trading on Thursday. 900 shares of the company were exchanged, compared to its average volume of 3. The company has a fifty day simple moving average of $32.86 and a 200-day simple moving average of $33.70. The company has a market capitalization of $27.27 million, a P/E ratio of -7.03 and a beta of -0.10. Bioqual has a 1-year low of $30.64 and a 1-year high of $43.55.
About Bioqual
Bioqual, Inc is a biomedical research and contract research organization based in Rockville, Maryland. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations involved in the development of medical products.
Its work focuses primarily on infectious diseases, vaccines, therapeutics, and diagnostics. Bioqual conducts laboratory and animal-model studies designed to evaluate the safety, efficacy, immunology, virology, and pharmacology of potential treatments and preventive products.
Read More
- Five stocks we like better than Bioqual
- Flywire’s Rapid Growth Faces a Q3 Test—Is Its Stock Already Too Expensive?
- Cologuard Is Working—So Why Isn’t Abbott Stock?
- Micron’s Taiwan Strike: A High-Stakes Fight Over AI Profits
- Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
